NCT02810106

Brief Summary

Cardiovascular diseases are important cause of death, and of these have highlighted the Coronary Artery Disease (CAD) and its various clinical manifestations. The chest pain suggestive of ischemic heart disease is frequent complaint in medical consultations and hospitalizations . Complementary tests and images exams for risk stratification as Cardiac Stress Test (ET), the Myocardial Perfusion scintigraphy of (SPECT) are established for risk stratification and assessment workup in suspected ischemic heart disease. Coronary tomography angiography (CTA) has emerged as a robust method for non-invasive assessment of CAD, showing data diagnostics that directly correlate with invasive coronary angiography. Recently, the Myocardial Perfusion by Tomography Computed (CTP) has emerged as a new technique to measure the flow limitation for coronary microcirculation. In clinical practice, the exercise testing with electrocardiogram changes compatible with myocardial ischemia can lead to other examinations for elucidation of ischemic etiology, the most usual myocardial scintigraphy. However, a SPECT without evidence of ischemia, does not explain ischemic electrocardiographic changes triggered by physical stress, although it is a good marker prognostic. A CTP is a emerging tool in the evaluation of myocardial ischemia. Recent studies point to a good accuracy of the method compared to nuclear medicine. To test this hypothesis, this study aims to evaluate whether the CTP has a better diagnostic performance in detecting of obstructive or not obstructive CAD compared to the SPECT in the population of patients with exercise stress testing compatible with myocardial ischemia, and the computed tomography angiography (CTA) as the reference method. In addition, data from the exercise test (functional capacity, hemodynamics, electrocardiogram changes) will be compared to findings of CTA and CTP.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jul 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 20, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 22, 2016

Completed
1 year until next milestone

Study Start

First participant enrolled

July 1, 2017

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
Last Updated

November 5, 2020

Status Verified

June 1, 2018

Enrollment Period

2.6 years

First QC Date

June 20, 2016

Last Update Submit

November 3, 2020

Conditions

Keywords

SpectStress TestMyocardial Perfusion CTCT angiography

Outcome Measures

Primary Outcomes (1)

  • myocardial perfusion data

    myocardial perfusion assessment by multidetector computed tomography in patients with ischemic exercise test

    2 years

Secondary Outcomes (1)

  • Anatomical data

    2 years

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Volunteers of the population with positive exercise test for ischemia

You may qualify if:

  • Patients with positive exercise test for ischemia Age\> 18 years

You may not qualify if:

  • Creatinine above 1.5 mg / dL and urea above 50 mg / dl and / or creatinine clearance \<than 60ml / kg / min
  • Pregnant women
  • Known patients allergic to iodinated contrast or dipyridamole
  • COPD and asthma
  • Systolic blood pressure \< 100 mmHg
  • Any other aspect that the researcher considers limiting the method

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Corpus Imagens

Pouso Alegre, Minas Geral, 375500000, Brazil

Location

Study Officials

  • Sergio Rodrigo Beraldo, Dr.

    Nuclear Medicine Service of Magsul and CT scan of Corpus Images

    PRINCIPAL INVESTIGATOR
  • Tiago Augusto Magalhaes, PhD

    Department Resonance and Cardiac Tomography of the Heart Institute of the University of Sao Paulo

    STUDY DIRECTOR
  • Carlos Eduardo Rochitte

    Department Resonance and Cardiac Tomography of the Heart Institute of the University of Sao Paulo

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
4 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 20, 2016

First Posted

June 22, 2016

Study Start

July 1, 2017

Primary Completion

February 1, 2020

Study Completion

November 1, 2020

Last Updated

November 5, 2020

Record last verified: 2018-06

Data Sharing

IPD Sharing
Will not share

Locations